Pro Medicus Ltd PME

Morningstar Rating
A$179.02 +1.26 (0.71%)
View Full Chart

Company Report

Not Much to Dislike About Pro Medicus' Business Model, but Shares Screen as Expensive

Pro Medicus’ strategy revolves around renewing existing contracts and winning new clients for its main product, Visage 7, while increasing its price point. The company won six out of six major public tenders it competed for in fiscal 2021, which often involved on-site pilot tests. While this likely highlights Visage 7’s current superior speed, scalability, and resilience, continued investment in research and development is imperative for the firm to remain at the forefront of innovation and consistently win contracts. Most of the firm’s expenses are allocated to over 40 software engineers with the main R&D center located in Berlin. The company also recently extended its R&D capability in New York in collaboration with NYU Langone Health in 2021. Its R&D efforts mostly revolve around software enhancements, program extensions, and research in artificial intelligence to assist in diagnoses.

Price vs Fair Value

PME is trading within a range we consider fairly valued.
Price
A$179.02
Fair Value
A$88.00
Uncertainty
High
1-Star Price
A$62.84
5-Star Price
A$57.30
Economic Moat
Hmhzv
Capital Allocation
Tdqjcfvc

Bulls Say, Bears Say

Bulls

Pro Medicus is well positioned to benefit from industry tailwinds such as cloud adoption, larger datasets, and remote access.

Bears

Product differentiation is unlikely to be durable, with low barriers to entry and larger competitors already utilizing server-side rendering and cloud-native architecture.

Trading Information

Previous Close Price
A$177.76
Day Range
A$177.00181.28
52-Week Range
A$74.40181.28
Bid/Ask
A$179.00 / A$179.25
Market Cap
A$18.71 Bil
Volume/Avg
133,962 / 270,150

Key Statistics

Price/Earnings (Normalized)
225.78
Price/Sales
116.08
Dividend Yield (Trailing)
0.22%
Dividend Yield (Forward)
0.25%
Total Yield
0.24%

Company Profile

Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.
Sector
Healthcare
Industry
Health Information Services
Stock Style Box
Large Growth
Total Number of Employees
75

Competitors

Valuation

Metric
PME
NAN
FPH
Price/Earnings (Normalized)
225.7867.56100.31
Price/Book Value
99.585.9011.93
Price/Sales
116.086.3912.00
Price/Cash Flow
228.5748.9049.10
Price/Earnings
PME
NAN
FPH

Financial Strength

Metric
PME
NAN
FPH
Quick Ratio
5.875.250.88
Current Ratio
5.986.161.83
Interest Coverage
8.2513.77
Quick Ratio
PME
NAN
FPH

Profitability

Metric
PME
NAN
FPH
Return on Assets (Normalized)
37.31%6.94%11.54%
Return on Equity (Normalized)
51.75%9.11%15.07%
Return on Invested Capital (Normalized)
49.07%7.18%13.94%
Return on Assets
PME
NAN
FPH

Health Information Services Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
GE HealthCare Technologies Inc Common Stock
GEHC
FghqjrhMkwdh$41.0 Bil
Veeva Systems Inc Class A
VEEV
YdthbqgdmvHkdf$33.1 Bil
Pro Medicus Ltd
PMCUF
Cgytdy$12.8 Bil
Solventum Corp
SOLV
Pqxmsx$11.6 Bil
Doximity Inc Class A
DOCS
Llmw$8.1 Bil
Tempus AI Inc Class A common stock
TEM
Krpmt$7.6 Bil
M3 Inc
MTHRF
Qzgmcbg$7.4 Bil
M3 Inc ADR
MTHRY
Cwtsryc$7.4 Bil
HealthEquity Inc
HQY
Vxnkpk$6.8 Bil
R1 RCM Inc
RCM
Cmg$6.0 Bil

Sponsor Center